Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Prothena Corp
(NQ:
PRTA
)
21.98
+0.27 (+1.24%)
Streaming Delayed Price
Updated: 1:21 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Prothena Corp
< Previous
1
2
Next >
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
March 14, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
February 23, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
February 16, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
January 31, 2023
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
December 14, 2022
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Proposed Public Offering of Ordinary Shares
December 13, 2022
From
Prothena Corporation plc
Via
Business Wire
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
December 12, 2022
From
Prothena Corporation plc
Via
Business Wire
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
November 21, 2022
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
From
Prothena Corporation plc
Via
Business Wire
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
November 03, 2022
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
October 27, 2022
From
Prothena Corporation plc
Via
GlobeNewswire
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
October 20, 2022
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...
Via
FinancialNewsMedia
Cognitive Assessment And Training Market Size Expected To Reach $15.65 Billion In 2028
May 04, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.